Epidemiology, clinical and biological characteristics, and prognosis of critically ill COVID 19 patients: a single-center experience through 4 successive waves

被引:0
作者
Tchakerian, Sonia [1 ]
Besnard, Noemie [1 ]
Brunot, Vincent [1 ]
Moulaire, Valerie [1 ]
Benchabane, Nacim [1 ]
Platon, Laura [1 ]
Daubin, Delphine [1 ]
Corne, Philippe [1 ]
Machado, Sonia [1 ]
Jung, Boris [1 ,2 ]
Bendiab, Eddine [1 ]
Landreau, Liliane [1 ]
Pelle, Corrine [1 ]
Larcher, Romaric [1 ]
Klouche, Kada [1 ,2 ]
机构
[1] Univ Montpellier, Lapeyronie Univ Hosp, Dept Intens Care Med, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier, France
[2] Univ Montpellier, French Inst Hlth & Med Res, French Natl Ctr Sci Res, Sch Med,PhyMedExp,INSERM,CNRS, Montpellier, France
来源
PNEUMONIA | 2024年 / 16卷 / 01期
关键词
SARS-CoV-2; ARDS; ICU; Mortality; Prognosis; VAP; Aspergillosis; CAPA; CORONAVIRUS DISEASE 2019; PULMONARY ASPERGILLOSIS; PNEUMONIA; MORTALITY; COHORT; TRENDS;
D O I
10.1186/s41479-024-00144-w
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
ObjectiveThe aim of this study was to describe the characteristics of patients admitted to the intensive care unit with severe pneumonia due to SARS-CoV-2, comparing them according to successive waves, and to identify prognostic factors for morbidity and mortality.Materials and methodsThis single-center retrospective observational descriptive study was conducted from March 10, 2020, to October 17, 2021. All adult patients admitted with SARS-CoV-2 pneumonia presenting acute respiratory failure were included. COVID 19 diagnosis was confirmed by RT-PCR testing of respiratory specimens. The primary endpoint was ICU mortality. Secondary endpoints were the occurrence of ventilator-associated pneumonia (VAP) or bronchopulmonary aspergillosis.ResultsOver the study period, 437 patients were included of whom 282 (65%) patients were ventilated for 9 [5;20] days. Among the studied population, 38% were treated for one or more episodes of VAP, and 22 (5%) for bronchopulmonary aspergillosis. ICU mortality was 26% in the first wave, then fell and stabilized at around 10% in subsequent waves (p = 0.02). Increased age, Charlson index, SOFA score and lactatemia on admission were predictive of mortality. Survival at 90 days was 85% (95% CI 82-88) and was unaffected by the presence of VAP. However, the occurrence of bronchopulmonary aspergillosis increased mortality to 36%.ConclusionIn this study, we observed mortality in the lower range of those previously reported. Risk factors for mortality mainly included age and previous comorbidities. The prognosis of these critically ill Covid 19 patients improved over the four waves, underlining the likely beneficial effect of vaccination and dexamethasone.
引用
收藏
页数:12
相关论文
共 43 条
  • [1] Trends in ICU Mortality From Coronavirus Disease 2019: A Tale of Three Surges
    Auld, Sara C.
    Harrington, Kristin R., V
    Adelman, Max W.
    Robichaux, Chad J.
    Overton, Elizabeth C.
    Caridi-Scheible, Mark
    Coopersmith, Craig M.
    Murphy, David J.
    [J]. CRITICAL CARE MEDICINE, 2022, 50 (02) : 245 - 255
  • [2] Managing ICU surge during the COVID-19 crisis: rapid guidelines
    Aziz, Shadman
    Arabi, Yaseen M.
    Alhazzani, Waleed
    Evans, Laura
    Citerio, Giuseppe
    Fischkoff, Katherine
    Salluh, Jorge
    Meyfroidt, Geert
    Alshamsi, Fayez
    Oczkowski, Simon
    Azoulay, Elie
    Price, Amy
    Burry, Lisa
    Dzierba, Amy
    Benintende, Andrew
    Morgan, Jill
    Grasselli, Giacomo
    Rhodes, Andrew
    Moller, Morten H.
    Chu, Larry
    Schwedhelm, Shelly
    Lowe, John J.
    Bin, Du
    Christian, Michael D.
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (07) : 1303 - 1325
  • [3] Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study
    Bartoletti, Michele
    Pascale, Renato
    Cricca, Monica
    Rinaldi, Matteo
    Maccaro, Angelo
    Bussini, Linda
    Fornaro, Giacomo
    Tonetti, Tommaso
    Pizzilli, Giacinto
    Francalanci, Eugenia
    Giuntoli, Lorenzo
    Rubin, Arianna
    Moroni, Alessandra
    Ambretti, Simone
    Trapani, Filippo
    Vatamanu, Oana
    Ranieri, Vito Marco
    Castelli, Andrea
    Baiocchi, Massimo
    Lewis, Russell
    Giannella, Maddalena
    Viale, Pierluigi
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E3606 - E3614
  • [4] ESCMID COVID-19 living guidelines: drug treatment and clinical management
    Bartoletti, Michele
    Azap, Ozlem
    Barac, Aleksandra
    Bussini, Linda
    Ergonul, Onder
    Krause, Robert
    Ramon Pano-Pardo, Jose
    Power, Nicholas R.
    Sibani, Marcella
    Szabo, Balint Gergely
    Tsiodras, Sotirios
    Verweij, Paul E.
    Zollner-Schwetz, Ines
    Rodriguez-Bano, Jesus
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (02) : 222 - 238
  • [5] COVID-19-associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID-19 patients
    Calderon-Parra, Jorge
    Mills-Sanchez, Patricia
    Moreno-Torres, Victor
    Tejado-Bravo, Sandra
    Romero-Sanchez, Isabel
    Balandin-Moreno, Barbara
    Calvo-Salvador, Marina
    Portero-Azorin, Francisca
    Garcia-Masedo, Sarela
    Munez-Rubio, Elena
    Ramos-Martinez, Antonio
    Fernandez-Cruz, Ana
    [J]. MYCOSES, 2022, 65 (05) : 541 - 550
  • [6] Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study
    Carbonell, Raquel
    Urgeles, Silvia
    Rodriguez, Alejandro
    Bodi, Maria
    Martin-Loeches, Ignacio
    Sole-Violan, Jordi
    Diaz, Emili
    Gomez, Josep
    Trefler, Sandra
    Vallverdu, Montserrat
    Murcia, Josefa
    Albaya, Antonio
    Loza, Ana
    Socias, Lorenzo
    Carlos Ballesteros, Juan
    Papiol, Elisabeth
    Vina, Lucia
    Sancho, Susana
    Nieto, Mercedes
    del Carmen Lorente, Maria
    Badallo, Oihane
    Fraile, Virginia
    Armestar, Fernando
    Estella, Angel
    Sanchez, Laura
    Sancho, Isabel
    Margarit, Antonio
    Moreno, Gerard
    [J]. LANCET REGIONAL HEALTH-EUROPE, 2021, 11
  • [7] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [8] Aspergillus-positive lower respiratory tract samples in patients with the acute respiratory distress syndrome: a 10-year retrospective study
    Contou, Damien
    Dorison, Matthieu
    Rosman, Jeremy
    Schlemmer, Frederic
    Gibelin, Aude
    Foulet, Francoise
    Botterel, Francoise
    Carteaux, Guillaume
    Razazi, Keyvan
    Brun-Buisson, Christian
    Dessap, Armand Mekontso
    de Prost, Nicolas
    [J]. ANNALS OF INTENSIVE CARE, 2016, 6
  • [9] The Extent of Aspergillosis in Critically Ill Patients With Severe Influenza Pneumonia: A Multicenter Cohort Study
    Coste, Anne
    Frerou, Aurelien
    Raute, Anais
    Couturaud, Francis
    Morin, Jean
    Egreteau, Pierre-Yves
    Blanc, Francois-Xavier
    Reignier, Jean
    Tadie, Jean-Marc
    Tran, Adissa
    Pronier, Charlotte
    Coste-Burel, Marianne
    Nevez, Gilles
    Gangneux, Jean-Pierre
    Le Pape, Patrice
    Ansart, Severine
    Tonnelier, Jean-Marie
    Bretonniere, Cedric
    Aubron, Cecile
    [J]. CRITICAL CARE MEDICINE, 2021, 49 (06) : 934 - 942
  • [10] Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort
    Delliere, Sarah
    Dudoignon, Emmanuel
    Fodil, Sofiane
    Voicu, Sebastian
    Collet, Magalie
    Oillic, Pierre-Antoine
    Salmona, Maud
    Depret, Francois
    Ghelfenstein-Ferreira, Theo
    Plaud, Benoit
    Chousterman, Benjamin
    Bretagne, Stephane
    Azoulay, Elie
    Mebazaa, Alexandre
    Megarbane, Bruno
    Alanio, Alexandre
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (05) : 790.e1 - 790.e5